Medications

IPF drug fails in new trial

A new study has demonstrated no significant benefit of taking the drug bosentan for idiopathic pulmonary fibrosis (IPF).

Diseases, Conditions, Syndromes

Therapy proves effective in subgroup of COPD patients

An antibody treatment reduces the rate of flare-ups by nearly 20 percent in patients with a subgroup of treatment-resistant chronic obstructive pulmonary disease (COPD), according to the results of two large international ...

Medical research

Research links telomere length to emphysema risk

Telomeres, the body's own cellular clocks, may be a crucial factor underlying the development of emphysema, according to research from Johns Hopkins University.

Genetics

Harnessing human evolution to advance precision medicine

Humans are still evolving, and Tatum Simonson, Ph.D., founder and co-director of the Center for Physiological Genomics of Low Oxygen at University of California School of Medicine, plans to use evolution to improve health ...

Diseases, Conditions, Syndromes

Heartburn treatment may extend survival in IPF patients

Patients with idiopathic pulmonary fibrosis (IPF) who report treatment for gastroespophageal reflux (GER) appear to have longer survival than IPF patients who are not treated for GERD, according to a new study from the University ...

Medical research

New targets for treating pulmonary hypertension found

Two new potential therapeutic targets for the treatment of pulmonary arterial hypertension, a deadly disease marked by high blood pressure in the lungs, have been identified by researchers at the University of Illinois at ...

page 3 from 11